Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation

Table 1 TERT promoter mutations, BRAF V600E mutation and ALK rearrangement in 243 Korean patients with thyroid cancer

	Patient	TERT promoter mutation				BRAF V600E	ALK rearrangement
	Patient	C228T	C250A	C250T	Overall	BRAF V600E	ALK rearrangement
WDTC without distant metastasis	192	0	0	0	0	142 (74 %)	0
PTC, classic	127	0	0	0	0	110 (87 %)	0
PTC, classic with TCF	11	0	0	0	0	10 (91 %)	0
PTC, EFV	9	0	0	0	0	1 (11 %)	0
PTC, IFV	7	0	0	0	0	5 (71 %)	0
PTC, tall cell	16	0	0	0	0	15 (94 %)	0
PTC, oncocytic	1	0	0	0	0	1 (100 %)	0
PTC, Warthin-like	1	0	0	0	0	0	0
FTC, minimally invasive	20	0	0	0	0	0	0
WDTC with distant metastasis	30	10 (33 %)	0	2 (7 %)	12 (40 %)	15 (50 %)	0
PTC, classic	14	3 (21 %)	0	0	3 (21 %)	7 (50 %)	0
PTC, classic with TCF	4	2 (50 %)	0	1 (25 %)	3 (75 %)	4 (100 %)	0
PTC, EFV	1	0	0	0	0	0	0
PTC, macrofollicular	1	0	0	0	0	0	0
PTC, tall cell	5	4 (80 %)	0	0	4 (80 %)	3 (60 %)	0
PTC, columnar cell	1	0	0	1 (100 %)	1 (100 %)	1 (100 %)	0
PTC, diffuse sclerosing	1	0	0	0	0	0	0
FTC, minimally invasive	2	1 (50 %)	0	0	0	0	0
FTC, widely invasive	1	0	0	0	1(100 %)	0	0
Poorly differentiated carcinoma	7	1 (14 %)	1 (14 %)	0	2 (29 %)	1 (14 %)	0
Anaplastic carcinoma	5	2 (40 %)	0	1 (20 %)	3 (60 %)	4 (80 %)	0
Medullary carcinoma	9	0	0	0	0	0	0

WDTC well-differentiated thyroid carcinoma, PTC papillary thyroid carcinoma, TCF tall cell features, EFV encapsulated follicular variant, IFV infiltrative follicular variant, FTC follicular thyroid carcinoma

ISSN: 1746-1596